Developer docs
API playgroundTry for free, no card

Search company profiles

NEXT Life Sciences

Full company profile

uuid0000wcd

Namestring
NEXT Life Sciences
Legal namestring
NEXT Life Sciences, Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

NEXT Life Sciences, Inc. is a clinical-stage private biotechnology company founded in 2021 and headquartered in Los Angeles, California, that is developing non-hormonal male contraceptive products. The company's lead asset, Plan A™, is a long-acting reversible male contraceptive device based on Vasalgel hydrogel technology licensed exclusively worldwide from the Parsemus Foundation (partnership established in 2022). The hydrogel is injected into the vas deferens, where it acts as a flexible filter blocking sperm flow; preclinical studies have shown the contraceptive effect can be reversed by dissolving and flushing the hydrogel. A second product, NLS-133, is a non-hormonal daily or on-demand pill designed to provide 24 hours of protection.

As of early 2026, both products are in Phase II clinical trials. The Plan A delivery system demonstrated 100% device success in early trials conducted in Canada (50 men) and Australia in 2025, and the U.S. patent for the Plan A medical device was granted in December 2025. Commercialization is targeted for approximately 2027 following FDA approval. The company has raised approximately $4 million in total seed funding ($1.55M in June 2023, plus a $2.5M seed extension in January 2024 led by The Family with participation from StartUp Health and Transform VC) and $400,000 in grant funding from the Male Contraceptive Initiative, and is planning a Series A round in 2026.

NEXT Life Sciences has no current revenue, no established pricing, and no commercial distribution channels. Its go-to-market approach upon approval will follow traditional pharmaceutical and medical device pathways (healthcare providers, clinics, and potentially pharmacies), targeting the estimated 17 million+ American men actively seeking new contraceptive options and the broader heterosexual couple segment where shared contraceptive responsibility is desired. The leadership team is anchored by operators from large medical-device and contraceptive companies (former CMO of Endosurgery at Boston Scientific; former CEO of the largest-selling contraceptive company at $1B+ revenue), supplemented by former FDA Chief Counsel Peter Barton Hutt on the advisory board.

Short descriptiontext

NEXT Life Sciences is a clinical-stage private biotechnology company developing Plan A, a long-acting reversible non-hormonal male contraceptive device using Vasalgel hydrogel, and NLS-133, a non-hormonal on-demand pill, both currently in Phase II trials with commercialization targeted for ~2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Luis Obispo, United States
HQ citystring
San Luis Obispo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
male contraceptive devices, non-hormonal contraception, reversible fertility control, clinical stage biopharmaceuticals, contraceptive drug development
Industry3 codes
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKAOAD
Male Reproductive & Sexual Medicine (Andrology)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Male Contraceptive Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Plan A Medical Device
TypeOne Time License
Description

Long-acting reversible male contraceptive device commercialized as a medical product. The company holds exclusive worldwide license for Vasalgel technology and plans market entry around 2027 following FDA approval.

einpresswire.com
2NLS-133 Pharmaceutical Product
TypeOne Time License
Description

Non-hormonal daily or on-demand pill for male contraception. Currently in Phase II clinical trials evaluating effectiveness through semen level measurements.

trial.medpath.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Plan A
Description

Long-acting, non-hormonal, reversible male contraceptive device using Vasalgel hydrogel technology, injected into the vas deferens to block sperm flow.

trial.medpath.com
+1 more record
Core offering1 text field

NEXT Life Sciences is developing two non-hormonal male contraceptive products: Plan A™, a long-acting reversible device that injects Vasalgel hydrogel into the vas deferens to block sperm flow and can be reversed by dissolving the hydrogel, and NLS-133, a non-hormonal on-demand or daily pill providing 24 hours of protection. Both candidates are in Phase II clinical trials, with the company holding an exclusive worldwide license for Vasalgel technology and a granted U.S. patent for the Plan A device.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100% delivery device success in clinical trials
+3 more records
Product overview1 text field

NEXT Life Sciences is developing two distinct male contraceptive products: Plan A™ is a long-acting, non-hormonal, reversible device that uses Vasalgel hydrogel injected into the vas deferens to block sperm flow, with reversibility achieved by dissolving and flushing the hydrogel; NLS-133 is a separate non-hormonal pill designed for 24-hour on-demand or daily use. Both products are non-hormonal contraceptives targeting the substantial market gap where over 17 million American men seek new contraceptive options. The company holds an exclusive worldwide license for the Vasalgel technology and has received patent protection for the Plan A device.

Product and service2 records
1Plan A™
CategoryMale contraceptive medical device
Description

A long-acting, non-hormonal, reversible male contraceptive device that injects Vasalgel hydrogel into the vas deferens where it acts as a flexible filter blocking sperm flow. The contraceptive effect can be reversed on-demand by dissolving and flushing the hydrogel. Targeted at adult men and couples seeking shared contraceptive responsibility, with commercialization planned around 2027 following FDA approval.

2NLS-133
CategoryNon-hormonal contraceptive pharmaceutical
Description

A non-hormonal male contraceptive pill designed for on-demand or daily use, providing 24 hours of protection. Currently in Phase II clinical trials evaluating participants' semen levels to demonstrate effectiveness. Targeted at individual men and couples seeking a non-hormonal, short-acting contraceptive option.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeOthersAnnounced on2025-08-29
Description

Former Chief Counsel at the U.S. Food & Drug Administration joined NEXT Life Sciences advisory board to help advance Plan A toward potential FDA approval. His appointment is intended to help navigate the regulatory pathway.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Parsemus Foundation initially developed Vasalgel technology and partnered with NEXT Life Sciences in 2022 to bring the product to market as an affordable and accessible birth control option for men. NEXT Life Sciences acquired exclusive worldwide license for the Vasalgel technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration for broader male contraceptive development, though this appears related to different research (JQ1 molecule study) rather than the company's primary products.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Contraline is developing ADAM, a long-acting reversible hydrogel-based male contraceptive injected into the vas deferens — the most direct mechanistic and clinical-stage competitor to NEXT Life Sciences' Plan A. Both companies target the same first-in-class non-hormonal reversible male contraceptive category.

TypeBroad incumbent
Description

AbbVie operates a broad reproductive health portfolio (Lo Loestrin, Lupron, Orilissa) and has the commercial footprint and balance sheet to enter the male contraceptive category either through acquisition of a company like NLS or through internal development of competing assets.

TypeEmerging player
Description

YourChoice Therapeutics is a venture-backed startup developing non-hormonal contraceptives for men and women, including a vas deferens-targeted approach. It overlaps with NEXT's male contraceptive focus and represents another emerging competitor in the non-hormonal reversible category.

TypeOthers
Description

The Population Council is a non-profit research organization that has historically driven much of the male contraceptive pipeline, including earlier work on Vasalgel-adjacent technologies. It functions as an enabling research partner and indirect ecosystem participant rather than a commercial competitor.

TypeBroad incumbent
Description

Bayer is a major incumbent in reproductive health with blockbuster contraceptive franchises (Mirena IUD, Yaz, etc.) and a deep women's health commercial infrastructure that could be leveraged to scale a male contraceptive. It is a broad comparator for go-to-market scale and a likely strategic acquirer.

TypeBroad incumbent
Description

TherapeuticsMD is a women's health pharmaceutical company with FDA-approved contraceptive and hormone therapy products. It represents a comparable commercial-stage reproductive health company and a potential strategic partner or acquirer for NLS at scale.

TypeBroad incumbent
Description

Organon is a global women's health-focused pharmaceutical company spun out of Merck with a broad contraceptive portfolio (e.g., Nexplanon, NuvaRing). While focused on female contraception today, Organon is a logical strategic acquirer or competitor if it expands into the male contraceptive market.

TypeBroad incumbent
Description

Dare Bioscience is a clinical-stage biopharmaceutical company focused on women's health, including contraceptive product candidates. It is a relevant comparator as a similarly-sized, publicly traded reproductive health developer pursuing novel contraceptive mechanisms.

TypeEmerging player
Description

Eppin Pharma is developing a non-hormonal oral male contraceptive pill targeting the Eppin protein on sperm — directly comparable to NLS-133 as a competing on-demand non-hormonal male pill. It is one of the few companies pursuing male contraception through a small-molecule oral route.

TypeOthers
Description

Hims & Hers is a consumer telehealth platform with a growing men's health category (including treatments historically limited to in-person visits). It is an adjacent — rather than direct — comparator for NLS's eventual consumer-facing male contraceptive distribution model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NEXT Life Sciences

Male Contraceptive Medical Devicesnextlifesciences.org

NEXT Life Sciences is a clinical-stage private biotechnology company developing Plan A, a long-acting reversible non-hormonal male contraceptive device using Vasalgel hydrogel, and NLS-133, a non-hormonal on-demand pill, both currently in Phase II trials with commercialization targeted for ~2027.

What NEXT Life Sciences does

NEXT Life Sciences, Inc. is a clinical-stage private biotechnology company founded in 2021 and headquartered in Los Angeles, California, that is developing non-hormonal male contraceptive products. The company's lead asset, Plan A™, is a long-acting reversible male contraceptive device based on Vasalgel hydrogel technology licensed exclusively worldwide from the Parsemus Foundation (partnership established in 2022). The hydrogel is injected into the vas deferens, where it acts as a flexible filter blocking sperm flow; preclinical studies have shown the contraceptive effect can be reversed by dissolving and flushing the hydrogel. A second product, NLS-133, is a non-hormonal daily or on-demand pill designed to provide 24 hours of protection.

As of early 2026, both products are in Phase II clinical trials. The Plan A delivery system demonstrated 100% device success in early trials conducted in Canada (50 men) and Australia in 2025, and the U.S. patent for the Plan A medical device was granted in December 2025. Commercialization is targeted for approximately 2027 following FDA approval. The company has raised approximately $4 million in total seed funding ($1.55M in June 2023, plus a $2.5M seed extension in January 2024 led by The Family with participation from StartUp Health and Transform VC) and $400,000 in grant funding from the Male Contraceptive Initiative, and is planning a Series A round in 2026.

NEXT Life Sciences has no current revenue, no established pricing, and no commercial distribution channels. Its go-to-market approach upon approval will follow traditional pharmaceutical and medical device pathways (healthcare providers, clinics, and potentially pharmacies), targeting the estimated 17 million+ American men actively seeking new contraceptive options and the broader heterosexual couple segment where shared contraceptive responsibility is desired. The leadership team is anchored by operators from large medical-device and contraceptive companies (former CMO of Endosurgery at Boston Scientific; former CEO of the largest-selling contraceptive company at $1B+ revenue), supplemented by former FDA Chief Counsel Peter Barton Hutt on the advisory board.

NEXT Life Sciences firmographics

Firmographics
Name
NEXT Life Sciences
Legal name
NEXT Life Sciences, Inc.
Website
https://nextlifesciences.org
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
NEXT Life Sciences is a clinical-stage private biotechnology company developing Plan A, a long-acting reversible non-hormonal male contraceptive device using Vasalgel hydrogel, and NLS-133, a non-hormonal on-demand pill, both currently in Phase II trials with commercialization targeted for ~2027.
Ownership category
akta.pro rank

NEXT Life Sciences industry classification

Industry
Product category
Male Contraceptive Medical Devices
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKAOAD
Male Reproductive & Sexual Medicine (Andrology)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Male contraceptive devices
  • Non-hormonal contraception
  • Reversible fertility control
  • Clinical stage biopharmaceuticals
  • Contraceptive drug development

Where NEXT Life Sciences is headquartered

Location

Headquarters

HQ city
San Luis Obispo
HQ country
United States
HQ region
North America

Offices2 records

Markets served

NEXT Life Sciences business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Plan A Medical Device: Long-acting reversible male contraceptive device commercialized as a medical product. The company holds exclusive worldwide license for Vasalgel technology and plans market entry around 2027 following FDA approval.
  2. NLS-133 Pharmaceutical Product: Non-hormonal daily or on-demand pill for male contraception. Currently in Phase II clinical trials evaluating effectiveness through semen level measurements.

Go-to-market motion2 records

Marketing channels4 records

NEXT Life Sciences product offering

Product offering

Core offering

NEXT Life Sciences is developing two non-hormonal male contraceptive products: Plan A™, a long-acting reversible device that injects Vasalgel hydrogel into the vas deferens to block sperm flow and can be reversed by dissolving the hydrogel, and NLS-133, a non-hormonal on-demand or daily pill providing 24 hours of protection. Both candidates are in Phase II clinical trials, with the company holding an exclusive worldwide license for Vasalgel technology and a granted U.S. patent for the Plan A device.

Product overview

NEXT Life Sciences is developing two distinct male contraceptive products: Plan A™ is a long-acting, non-hormonal, reversible device that uses Vasalgel hydrogel injected into the vas deferens to block sperm flow, with reversibility achieved by dissolving and flushing the hydrogel; NLS-133 is a separate non-hormonal pill designed for 24-hour on-demand or daily use. Both products are non-hormonal contraceptives targeting the substantial market gap where over 17 million American men seek new contraceptive options. The company holds an exclusive worldwide license for the Vasalgel technology and has received patent protection for the Plan A device.

Differentiator

Problem solved

Functional benefit

Brands

  • Plan A: Long-acting, non-hormonal, reversible male contraceptive device using Vasalgel hydrogel technology, injected into the vas deferens to block sperm flow.
  • NLS-133

Products and services

  • Plan A™ A long-acting, non-hormonal, reversible male contraceptive device that injects Vasalgel hydrogel into the vas deferens where it acts as a flexible filter blocking sperm flow. The contraceptive effect can be reversed on-demand by dissolving and flushing the hydrogel. Targeted at adult men and couples seeking shared contraceptive responsibility, with commercialization planned around 2027 following FDA approval.
  • NLS-133 A non-hormonal male contraceptive pill designed for on-demand or daily use, providing 24 hours of protection. Currently in Phase II clinical trials evaluating participants' semen levels to demonstrate effectiveness. Targeted at individual men and couples seeking a non-hormonal, short-acting contraceptive option.

Quantifiable outcome

  • 100% delivery device success in clinical trials
  • +3 more outcomes

Companies that use NEXT Life Sciences

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

NEXT Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

NEXT Life Sciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • Peter Barton HuttminorOthers · 29 August 2025Former Chief Counsel at the U.S. Food & Drug Administration joined NEXT Life Sciences advisory board to help advance Plan A toward potential FDA approval. His appointment is intended to help navigate the regulatory pathway.
  • Parsemus FoundationcoreStrategic or Co-development Partner · 1 January 2022Parsemus Foundation initially developed Vasalgel technology and partnered with NEXT Life Sciences in 2022 to bring the product to market as an affordable and accessible birth control option for men. NEXT Life Sciences acquired exclusive worldwide license for the Vasalgel technology.
  • Cornell UniversityminorStrategic or Co-development PartnerResearch collaboration for broader male contraceptive development, though this appears related to different research (JQ1 molecule study) rather than the company's primary products.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

NEXT Life Sciences competitors and assessment

Company assessment

Direct peers

  • Contraline: Contraline is developing ADAM, a long-acting reversible hydrogel-based male contraceptive injected into the vas deferens — the most direct mechanistic and clinical-stage competitor to NEXT Life Sciences' Plan A. Both companies target the same first-in-class non-hormonal reversible male contraceptive category.

Broad incumbents

  • AbbVie: AbbVie operates a broad reproductive health portfolio (Lo Loestrin, Lupron, Orilissa) and has the commercial footprint and balance sheet to enter the male contraceptive category either through acquisition of a company like NLS or through internal development of competing assets.
  • Bayer: Bayer is a major incumbent in reproductive health with blockbuster contraceptive franchises (Mirena IUD, Yaz, etc.) and a deep women's health commercial infrastructure that could be leveraged to scale a male contraceptive. It is a broad comparator for go-to-market scale and a likely strategic acquirer.
  • TherapeuticsMD: TherapeuticsMD is a women's health pharmaceutical company with FDA-approved contraceptive and hormone therapy products. It represents a comparable commercial-stage reproductive health company and a potential strategic partner or acquirer for NLS at scale.
  • Organon: Organon is a global women's health-focused pharmaceutical company spun out of Merck with a broad contraceptive portfolio (e.g., Nexplanon, NuvaRing). While focused on female contraception today, Organon is a logical strategic acquirer or competitor if it expands into the male contraceptive market.
  • Dare Bioscience: Dare Bioscience is a clinical-stage biopharmaceutical company focused on women's health, including contraceptive product candidates. It is a relevant comparator as a similarly-sized, publicly traded reproductive health developer pursuing novel contraceptive mechanisms.

Emerging players

  • YourChoice Therapeutics: YourChoice Therapeutics is a venture-backed startup developing non-hormonal contraceptives for men and women, including a vas deferens-targeted approach. It overlaps with NEXT's male contraceptive focus and represents another emerging competitor in the non-hormonal reversible category.
  • Eppin Pharma: Eppin Pharma is developing a non-hormonal oral male contraceptive pill targeting the Eppin protein on sperm — directly comparable to NLS-133 as a competing on-demand non-hormonal male pill. It is one of the few companies pursuing male contraception through a small-molecule oral route.

Others

  • Population Council: The Population Council is a non-profit research organization that has historically driven much of the male contraceptive pipeline, including earlier work on Vasalgel-adjacent technologies. It functions as an enabling research partner and indirect ecosystem participant rather than a commercial competitor.
  • Hims & Hers Health: Hims & Hers is a consumer telehealth platform with a growing men's health category (including treatments historically limited to in-person visits). It is an adjacent — rather than direct — comparator for NLS's eventual consumer-facing male contraceptive distribution model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

NEXT Life Sciences social profiles

Digital presence

NEXT Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NEXT Life Sciences leadership team

Management profile

Number of profiles

Profiles7 records

NEXT Life Sciences funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NEXT Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NEXT Life Sciences

What does NEXT Life Sciences do?

NEXT Life Sciences is developing two non-hormonal male contraceptive products: Plan A™, a long-acting reversible device that injects Vasalgel hydrogel into the vas deferens to block sperm flow and can be reversed by dissolving the hydrogel, and NLS-133, a non-hormonal on-demand or daily pill providing 24 hours of protection. Both candidates are in Phase II clinical trials, with the company holding an exclusive worldwide license for Vasalgel technology and a granted U.S. patent for the Plan A device.

Is NEXT Life Sciences a public or private company?

NEXT Life Sciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was NEXT Life Sciences founded?

NEXT Life Sciences was founded in 2020. It employs 11 to 50 people.

Where is NEXT Life Sciences based?

NEXT Life Sciences is headquartered in San Luis Obispo, United States, in the North America region.

How does NEXT Life Sciences make money?

Two revenue lines are on record. Plan A Medical Device is the primary driver. The others are NLS-133 Pharmaceutical Product.

Who are NEXT Life Sciences's main competitors?

Contraline is listed as a direct peer. Broad incumbents are AbbVie, Bayer, TherapeuticsMD, Organon and Dare Bioscience. Emerging players are YourChoice Therapeutics and Eppin Pharma. Others are Population Council and Hims & Hers Health.

Does NEXT Life Sciences have an API?

No public API is recorded for NEXT Life Sciences.

What industry is NEXT Life Sciences in?

NEXT Life Sciences's product category is Male Contraceptive Medical Devices. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAKAOAD, Male Reproductive & Sexual Medicine (Andrology). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MobiHealthNewsHIMSSCast: Male birth control pill, implant aim to prevent pregnancyNEXT Life Sciences founder L.R. Fox discusses the company's male contraceptives Plan A and PausePill, which offer long-acting and on-demand protection. The company targets men who want to turn off fertility temporarily or take a daily pill. The podcast episode also covers other contraceptive news.IolThe era of male birth control is approachingMale contraceptives like RISUG, Plan A, and ADAM are being developed to block sperm passage via hydrogel injection. Next Life Sciences' Plan A completed Phase 2 trials with zero sperm counts and aims for FDA approval in 2028. The documentary highlights the long-standing effort and potential for gender equity.YahooThe era of male birth control may be nearingMale reversible contraceptives are advancing, with companies developing hydrogel-based vas-occlusive methods like RISUG, Plan A, and ADAM. Next Life Sciences completed Phase 2 trials for Plan A, showing zero sperm counts, and aims for FDA approval in 2028. The documentary highlights the long history and gender equity implications.New York PostNew male birth control options are on the way — including a pill that could make orgasms even betterNEXT Life Sciences is developing male birth control options, including PausePill, an on-demand pill, and Plan A, a reversible implant. A 2024 survey of 18,000+ men found 61% would try a new male contraceptive within its first year. The company aims to bring PausePill to market within two years.PlanaformenNEXT Life Sciences Raises $1.55M for Plan A, Its Male ContraceptiveNEXT Life Sciences has raised $1.55 million in funding for Plan A, a male contraceptive product utilizing Vasalgel hydrogel technology. Plan A works by injecting the hydrogel into the vas deferens where it acts as a flexible filter blocking sperm flow, and preclinical studies have demonstrated the contraceptive effect can be reversed by dissolving and flushing the hydrogel. The company plans to initiate clinical trials by the end of 2023.Spherical InsightsBreakthrough takes big step toward safe, reversible male contraceptionResearchers at Cornell University demonstrated in a six-year mouse study that the molecule JQ1 can temporarily block sperm production by interrupting meiosis, the cell-division process responsible for creating reproductive cells, without causing permanent fertility loss; normal sperm production and fertility returned within six weeks of stopping treatment. Published in the Proceedings of the National Academy of Sciences, the breakthrough is considered one of the most significant advances toward a safe, reversible, non-hormonal male contraceptive and could enable future products such as quarterly injections or skin patches. Growing investments from the Bill & Melinda Gates Foundation and increasing commercial activity by companies including Contraline, YourChoice Therapeutics, and NEXT Life Sciences are accelerating the path toward human applications and broader male birth-control options.MedpathNEXT Life Sciences Advances Two Non-Hormonal Male Contraceptives Into Phase II Clinical TrialsNEXT Life Sciences has advanced two non-hormonal male contraceptive candidates, Plan A™ and NLS-133, into Phase II clinical trials, with Plan A™ demonstrating 100% delivery device success in early trials conducted in Australia and Canada during 2025. NLS-133 is designed as a 24-hour on-demand or daily-use pill, currently evaluating participants' semen levels to demonstrate effectiveness. The development addresses a substantial market gap, with over 17 million American men actively seeking new contraceptive options and research indicating 70% of men willing to try new male contraceptive methods, while the company plans a Series A funding round in 2026 following an oversubscribed Seed round.Weekly VoiceTwo Male Birth Control Options Advance Into Phase II Clinical TrialsNEXT Life Sciences announced that its two male birth control options, Plan A™ (a long-acting reversible device) and NLS-133 (a daily or on-demand pill), have both entered Phase II clinical trials after successful early-stage results in Australia and Canada. The company positions itself as a leader in male contraception, citing that half of pregnancies worldwide remain unplanned and that the burden of contraception falls disproportionately on women. NEXT Life Sciences is planning a Series A funding round in 2026 following an oversubscribed Seed round.PR NewswireTwo Male Birth Control Options Advance Into Phase II Clinical TrialsNEXT Life Sciences announced that its two male birth control products have advanced into Phase II clinical trials: Plan A™, a long-acting, non-hormonal, reversible-on-demand contraceptive that showed 100% success in early trials in Australia and Canada and entered Phase II in October 2025, and NLS-133, a non-hormonal male contraceptive pill providing 24-hour protection as an on-demand or daily option, also now in Phase II trials. The company is planning a Series A funding round in 2026 following an oversubscribed Seed round, positioning itself to lead in the male contraception space amid unmet demand and evidence that 70% of men are willing to try new methods.PlanaformenTwo Male Birth Control Options Advance Into Phase II Clinical TrialsNEXT Life Sciences has advanced two non-hormonal male contraceptive options, Plan A™ and NLS-133, into Phase II clinical trials. Plan A™ demonstrated 100% delivery device success in early trials conducted in Australia and Canada during 2025, while NLS-133 is designed as an on-demand or daily pill providing 24 hours of protection. The development addresses a substantial unmet need, with over 17 million American men actively seeking new contraceptive options and research indicating that 70% of men would be willing to try new male contraceptive methods, with a Series A funding round planned for 2026.